Press Release

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

May 7, 2024

- Presentations to be webcast on -

ALAMEDA, Calif.--(BUSINESS WIRE)--May 7, 2024-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:

  • BofA Securities 2024 Health Care Conference: Exelixis is scheduled to present at 2:20 p.m. ET / 11:20 a.m. PT on Tuesday, May 14 in Las Vegas.
  • Citizens JMP Life Sciences Conference: Exelixis is scheduled to present at 9:30 a.m. ET / 6:30 a.m. PT on Tuesday, May 14 in New York City.
  • RBC Capital Markets 2024 Global Healthcare Conference: Exelixis is scheduled to present at 2:35 p.m. ET / 11:35 a.m. PT on Tuesday, May 14 in New York City.

To access the webcast links, log onto and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

Investors Contact:
Varant Shirvanian
Director, Investor Relations
Exelixis, Inc.

Media Contact:
Hal Mackins
For Exelixis, Inc.

Source: Exelixis, Inc.